![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
EDAP TMS SA | NASDAQ:EDAP | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.123 | 2.47% | 5.108 | 4.96 | 5.20 | 5.108 | 5.108 | 5.108 | 102 | 14:59:59 |
Six months
ended
|
Six months
ended
|
|||||||
(in millions of euros)
|
June 30, 2013
|
June 30, 2012
|
||||||
Total revenues
|
10,4 | 11,0 | ||||||
Total net sales
|
10,4 | 11,0 | ||||||
Of which HIFU
|
2,3 | 2,4 | ||||||
Of which UDS
|
8,1 | 8,5 | ||||||
Total cost of sales
|
(6,6 | ) | (6,7 | ) | ||||
Gross profit
|
3,8 | 4,3 | ||||||
Gross profit as a percentage of total net sales
|
36.7 | % | 39.2 | % | ||||
Total operating expenses
|
(6,5 | ) | (6.2 | ) | ||||
Loss from operations
|
(2,6 | ) | (1.9 | ) | ||||
Net income (loss)
|
(4,1 | ) | (5.9 | ) |
Six months
ended
|
Six months
ended
|
|||||||
(in thousands of euros)
|
June 30, 2013
|
June 30, 2012
|
||||||
Net cash used in operating activities
|
(2,228 | ) | (24 | ) | ||||
Net cash used in investing activities
|
(1,467 | ) | (2,117 | ) | ||||
Net cash provided/(used) in financing activities
|
1,584 | 1,830 | ||||||
Net effect of exchange rate changes
|
412 | (34 | ) | |||||
Net increase/(decrease) in cash and cash equivalents
|
(1,699 | ) | (345 | ) | ||||
Cash and cash equivalents at the beginning of the period
|
7,041 | 4,900 | ||||||
Cash and cash equivalents at the end of the period
|
5,342 | 4,555 | ||||||
Total cash and cash equivalents, and short-term investments
as of June 30
|
7,373 | 8,068 |
-
|
a net loss of €4.1 million;
|
-
|
the elimination of €1.2 million of net expenses without an effect on cash, including €0.4 million of depreciation and amortization, €0.4 million of change in long-term provisions and €0.4 million due to variation of the fair value of financial instruments (debentures and warrants);
|
-
|
a decrease in trade accounts receivable of €3.0 million;
|
-
|
an increase in inventories of €1.1 million;
|
-
|
a decrease in payables of €1.5 million;
|
-
|
a decrease in prepaid expenses of €0.1 million; and
|
-
|
an increase in other current liabilities of €0.2 million.
|
-
|
a net loss of €5.9 million;
|
-
|
the elimination of €4.2 million of net expenses without an effect on cash, including €0.5 million of depreciation and amortization, €0.2 million of change in long-term provisions and €3.6 million due to variation of the fair value of financial instruments (debentures and warrants);
|
-
|
a decrease in trade accounts receivable of €3.3 million;
|
-
|
an increase in inventories of €0.6 million;
|
-
|
a decrease in payables of €1.4 million;
|
-
|
a decrease in prepaid expenses of €0.1 million; and
|
-
|
an increase in other current liabilities of €0.2 million.
|
Index
|
||
Consolidated Balance Sheets (Unaudited) as of June 30, 2013 and December 31, 2012
|
7
|
|
Consolidated Statement of Income (Unaudited) for the periods ended June 30, 2013 and 2012
|
8
|
|
Consolidated Statement of Shareholders' Equity (Unaudited) for the period ended June 30, 2013
|
9
|
|
Consolidated Statements of Cash Flows (Unaudited) for the periods ended June 30, 2013 and 2012
|
10
|
|
Notes to Consolidated Interim Financial Statements
|
11
|
ASSETS
|
Notes
|
06-30-2013 | 12-31-2012 | |||||||||
Current assets
|
||||||||||||
Cash and cash equivalents
|
2 | 5,342 | 7,041 | |||||||||
Current portion of net trade accounts and notes receivable
|
7,577 | 11,148 | ||||||||||
Other receivables
|
1,131 | 842 | ||||||||||
Inventories
|
3 | 5,060 | 4,263 | |||||||||
Deferred tax assets
|
29 | 32 | ||||||||||
Other assets, current portion
|
300 | 367 | ||||||||||
Short-term investment
|
2 | 2,030 | 1,036 | |||||||||
Total current assets
|
21,470 | 24,729 | ||||||||||
Property and equipment, net
|
2,055 | 2,035 | ||||||||||
Intangible assets, net
|
53 | 71 | ||||||||||
Goodwill
|
2,412 | 2,412 | ||||||||||
Deposits
|
438 | 396 | ||||||||||
Other non-current assets
|
513 | 801 | ||||||||||
Total assets
|
26,939 | 30,444 | ||||||||||
LIABILITIES AND SHAREHOLDERS’ EQUITY
|
||||||||||||
Current liabilities
|
||||||||||||
Trade accounts and notes payable
|
4,762 | 6,336 | ||||||||||
Deferred revenues, current portion
|
985 | 885 | ||||||||||
Social security and other payroll withholdings taxes
|
716 | 729 | ||||||||||
Employee absences compensation
|
529 | 473 | ||||||||||
Other accrued liabilities
|
1,903 | 1,940 | ||||||||||
Short-term borrowings
|
4 | 1,552 | 2,095 | |||||||||
Current portion of capital lease obligations
|
5 | 303 | 459 | |||||||||
Current portion of long-term debt
|
6 | 152 | 207 | |||||||||
Total current liabilities
|
10,902 | 13,124 | ||||||||||
Deferred revenues, non current
|
- | 79 | ||||||||||
Capital lease obligations, non current
|
5 | 468 | 494 | |||||||||
Non convertible debentures carried at fair value
|
6 | - | 4,416 | |||||||||
Financial instruments carried at fair value
|
6 | 3,413 | 1,754 | |||||||||
Long-term debt, non current
|
6 | 312 | 415 | |||||||||
Other long-term liabilities
|
1,937 | 1,999 | ||||||||||
Total liabilities
|
17,032 | 22,282 | ||||||||||
Shareholders’ equity
|
||||||||||||
Common stock, €0.13 par value;
22,171,198 shares issued and 21,789,670 shares outstanding; 18,753,757 shares issued and 18,372,229 shares outstanding
at June 30, 2013 and at December 31, 2012, respectively
|
2,882 | 2,438 | ||||||||||
Additional paid-in capital
|
51,209 | 45,791 | ||||||||||
Retained earnings
|
(39,648 | ) | (35,569 | ) | ||||||||
Cumulative other comprehensive loss
|
(3,365 | ) | (3,327 | ) | ||||||||
Treasury stock, at cost; 381,528 shares at June 30’13 & at Dec.31, 2012
|
(1,172 | ) | (1,172 | ) | ||||||||
Total shareholders’ equity
|
9,907 | 8,161 | ||||||||||
Total liabilities and shareholders’ equity
|
26,939 | 30,444 |
Notes
|
6 months ended
June 30, 2013
|
6 months ended
June 30, 2012
|
||||||||||
Sales of goods
|
5,944 | 6,212 | ||||||||||
Sales of RPPs & leases
|
1,970 | 2,201 | ||||||||||
Sales of spare parts and services
|
2,512 | 2,550 | ||||||||||
Total sales
|
10,426 | 10,963 | ||||||||||
Other revenues
|
3 | - | ||||||||||
Total revenues
|
10,429 | 10,963 | ||||||||||
Cost of goods
|
(3,612 | ) | (3,575 | ) | ||||||||
Cost of RPPs & leases
|
(1,122 | ) | (1,243 | ) | ||||||||
Cost of spare parts and services
|
(1,870 | ) | (1,850 | ) | ||||||||
Total cost of sales
|
(6,604 | ) | (6,667 | ) | ||||||||
Gross profit
|
3,825 | 4,296 | ||||||||||
Research and development expenses
|
(1,578 | ) | (1,563 | ) | ||||||||
Selling and marketing expenses
|
(3,094 | ) | (2,959 | ) | ||||||||
General and administrative expenses
|
(1,802 | ) | (1,718 | ) | ||||||||
Non-recurring operating expenses
|
- | - | ||||||||||
Loss from operations
|
(2,649 | ) | (1,943 | ) | ||||||||
Financial (expense) income, net
|
8 | (612 | ) | (3,941 | ) | |||||||
Foreign currency exchange gain (loss), net
|
(757 | ) | (11 | ) | ||||||||
Other income (expense), net
|
1 | 40 | ||||||||||
Income (loss) before taxes
|
(4,017 | ) | (5,855 | ) | ||||||||
Income tax (expense) benefit
|
(61 | ) | (25 | ) | ||||||||
Net income (loss)
|
(4,078 | ) | (5,880 | ) | ||||||||
Basic net earnings (loss) per share
|
(0.21 | ) | (0.32 | ) | ||||||||
Shares outstanding
|
19,321,827 | 18,257,273 | ||||||||||
Diluted net earnings (loss) per share
(1)
|
(0.21 | ) | (0.32 | ) | ||||||||
Diluted shares outstanding
(1)
|
19,321,827 | 18,619,191 |
(1)
|
Due to the net losses in 2012 and 2013, the assumed net exercise of stock options/warrants and stock relating to the convertible bonds in this year was excluded, as the effect would have been anti-dilutive.
|
Number of
Shares
outstanding
|
Common
Stock
|
Additional
paid-in
Capital
|
Retained
Earnings
|
Cumulative
Other
Compre-
hensive
Income
(loss)
|
Treasury
Stock
|
Total
|
||||||||||||||||||||||
Balance as of December 31, 2012
|
18,372,229 | 2,438 | 45,791 | (35,569 | ) | (3,327 | ) | (1,172 | ) | 8,161 | ||||||||||||||||||
Net income
|
(5,880 | ) | (5,880 | ) | ||||||||||||||||||||||||
Translation adjustment
|
(38 | ) | (38 | ) | ||||||||||||||||||||||||
Warrants and stock options granted
|
192 | 192 | ||||||||||||||||||||||||||
Capital increase
|
3,417,441 | 444 | 5,226 | 5,670 | ||||||||||||||||||||||||
Balance as of June 30, 2013
|
21,789,670 | 2,882 | 51,209 | (39,648 | ) | (3,365 | ) | (1,172 | ) | 9,907 |
6 months ended
June 30, 2013
|
6 months ended
June 30, 2012
|
|||||||
Cash flows from operating activities
|
||||||||
Net income (loss)
|
(4,078 | ) | (5,880 | ) | ||||
Adjustments to reconcile net loss to net cash used in operating activities:
|
||||||||
Depreciation and amortization
|
428 | 453 | ||||||
Change in fair value
|
363 | 3,563 | ||||||
Other Non-cash compensation
|
208 | 94 | ||||||
Change in allowances for doubtful accounts & slow-moving inventories
|
106 | 83 | ||||||
Change in long-term provisions
|
(79 | ) | (178 | ) | ||||
Net capital loss on disposals of assets
|
188 | 233 | ||||||
Deferred tax expense/(benefit)
|
(36 | ) | (6 | ) | ||||
Operating cash flow
|
(2,900 | ) | (1,638 | ) | ||||
Increase/Decrease in operating assets and liabilities:
|
||||||||
Decrease/(Increase) in trade accounts and notes and other receivables
|
3,303 | 3,128 | ||||||
Decrease/(Increase) in inventories
|
(1,051 | ) | (633 | ) | ||||
Decrease/(Increase) in other assets
|
(295 | ) | 309 | |||||
(Decrease)/Increase in trade accounts and notes payable
|
(1,536 | ) | (1,389 | ) | ||||
(Decrease)/Increase in accrued expenses, other current liabilities
|
251 | 200 | ||||||
Net increase/decrease in operating assets and liabilities
|
672 | 1,615 | ||||||
Net cash used in operating activities
|
(2,228 | ) | (24 | ) | ||||
Cash flows from investing activities:
|
||||||||
Additions to capitalized assets produced by the Company
|
(392 | ) | (167 | ) | ||||
Net proceeds from sale of leased back assets
|
133 | 15 | ||||||
Acquisitions of property and equipment
|
(134 | ) | (63 | ) | ||||
Acquisitions of intangible assets
|
(40 | ) | ||||||
Acquisitions of short term investments
|
(995 | ) | (1,942 | ) | ||||
Net proceeds from sale of assets
|
- | |||||||
Decrease/(Increase) in deposits and guarantees
|
(79 | ) | 79 | |||||
Net cash used in investing activities
|
(1,467 | ) | (2,117 | ) | ||||
Cash flow from financing activities:
|
||||||||
Proceeds from capital increase
|
5,670 | 2,200 | ||||||
Proceeds from long term borrowings, net of financing costs
|
2,950 | 1,821 | ||||||
Repayment of long term borrowings
|
(6,114 | ) | (2,030 | ) | ||||
Repayment of obligations under capital leases
|
(379 | ) | (262 | ) | ||||
Increase/(decrease) in bank overdrafts and short-term borrowings
|
(543 | ) | 101 | |||||
Net cash used in financing activities
|
1,584 | 1,830 | ||||||
Net effect of exchange rate changes on cash and cash equivalents
|
412 | (34 | ) | |||||
Net decrease in cash and cash equivalents
|
(1,699 | ) | (345 | ) | ||||
Cash and cash equivalents at beginning of year
|
7,041 | 4,900 | ||||||
Cash and cash equivalents at end of period
|
5,342 | 4,555 |
Leasehold improvements
|
10 years or lease term if shorter | ||
Equipment
|
3-10 years | ||
Furniture, fixtures, fittings and other
|
2-10 years |
Patents
|
5 years |
Licenses
|
5 years |
Trade name and trademark
|
7 years |
·
|
assets and liabilities are translated at year-end exchange rates;
|
·
|
shareholders’ equity is translated at historical exchange rates (as of the date of contribution);
|
·
|
statement of income items are translated at average exchange rates for the year; and
|
·
|
translation gains and losses are recorded in a separate component of shareholders’ equity.
|
06-30-2013 | 12-31-2012 (1) | |||||||
Weighted-average expected life (years)
|
6.25 | — | ||||||
Expected volatility rates
|
71 | % | — | |||||
Expected dividend yield
|
— | — | ||||||
Risk-free interest rate
|
1.35 | % | — | |||||
Weighted-average exercise price (€)
|
1.91 | — | ||||||
Weighted-average fair value of options granted during the year (€)
|
1.32 | — |
-
|
Ownership is transferred to the lessee by the end of the lease term;
|
-
|
The lease contains a bargain purchase option;
|
-
|
The lease term is at least 75% of the property's estimated remaining economic life;
|
-
|
The present value of the minimum lease payments at the beginning of the lease term is 90% or more of the fair value of the leased property to the lessor at the inception date.
|
06-30-2013 | 12-31-2012 | |||||||
Total cash and cash equivalents
|
5,342 | 7,041 | ||||||
Short term investments
|
2,030 | 1,036 | ||||||
Total cash and short term investments
|
7,373 | 8,077 |
06-30-2013 | 12-31-2012 | |||||||
Components, spare parts
|
3,984 | 4,032 | ||||||
Work-in-progress
|
1,074 | 566 | ||||||
Finished goods
|
963 | 600 | ||||||
Total gross inventories
|
6,021 | 5,198 | ||||||
Less: provision for slow-moving inventory
|
(962 | ) | (934 | ) | ||||
Total
|
5,060 | 4,263 |
‘000 Euros
|
Amount
|
Maturation
|
Interest rate
|
EDAP-TMS France SAS
|
1,000
|
October 19, 2013
|
Euribor + 0,5%
|
06-30-2013 | 12-31-2012 | |||||||
Japanese yen term loan
|
393 | 497 | ||||||
Italy term loan
|
62 | 114 | ||||||
Malaysia term loan
|
9 | 11 | ||||||
Total long term debt
|
464 | 622 | ||||||
Less current portion
|
(152 | ) | (207 | ) | ||||
Total long-term portion
|
312 | 415 |
Amount
|
Maturation
|
Interest rate
|
|
EDAP Technomed Co. Ltd
|
10,000,000
|
March 31, 2015
|
0.10%
|
55,000,000
|
June 30, 2018
|
1.80%
|
|
10,000,000
|
June 30, 2018
|
0.10%
|
06-30-2013 | 12-31-2012 | |||||||
Non Convertible Debentures
|
- | 4,416 | ||||||
Less current portion
|
- | - | ||||||
Total long-term portion
|
- | 4,416 |
06-30-2013 | 12-31-2012 | |||||||
Investor Warrants
|
3,119 | 1,571 | ||||||
Placement Agent Warrants
|
294 | 183 | ||||||
Total
|
3,413 | 1,754 | ||||||
Less current portion
|
- | - | ||||||
Total long-term portion
|
3,413 | 1,754 |
-
|
Share price at closing date: $1.95
|
-
|
Strike price of warrants: $2.75
|
-
|
Risk free interest rate at 5 years: 1.05%
|
-
|
Share price volatility: 120%
|
-
|
Share price at closing date: $2.04
|
-
|
Strike price of warrants: $2.75
|
-
|
Risk free interest rate at 5 years: 0.59%
|
-
|
Share price volatility: 113%
|
-
|
Share price at closing date: $2.72
|
-
|
Strike price of warrants: $2.75
|
-
|
Risk free interest rate at 5 years: 0.94%
|
-
|
Share price volatility: 72%
|
-
|
Share price at closing date: $1.95
|
-
|
Strike price of warrants: $2.5
|
-
|
Risk free interest rate at 4.5 years: 0.92%
|
-
|
Share price volatility: 120%
|
-
|
Share price at closing date: $2.04
|
-
|
Strike price of warrants: $2.5
|
-
|
Risk free interest rate at 4.5 years: 0.50%
|
-
|
Share price volatility: 113%
|
-
|
Share price at closing date: $2.72
|
-
|
Strike price of warrants: $2.5
|
-
|
Risk free interest rate at 4.5 years: 0.75%
|
-
|
Share price volatility: 72%
|
-
|
Share price at closing date: $3.96
|
-
|
Strike price of warrants: $4.25
|
-
|
Risk free interest rate at 5.5 years: 1.07%
|
-
|
Share price volatility: 71%
|
-
|
Share price at closing date: $2.72
|
-
|
Strike price of warrants: $4.25
|
-
|
Risk free interest rate at 5.5 years: 1.52%
|
-
|
Share price volatility: 71%
|
-
|
Share price at closing date: $3.96
|
-
|
Strike price of warrants: $5.00
|
-
|
Risk free interest rate at 3 years: 0.36%
|
-
|
Share price volatility: 72%
|
-
|
Share price at closing date: $2.72
|
-
|
Strike price of warrants: $5.00
|
-
|
Risk free interest rate at 3 years: 0.64%
|
-
|
Share price volatility: 72%
|
2013
|
92 | |||
2014
|
99 | |||
2015
|
80 | |||
2016
|
367 | |||
2017
|
1,583 | |||
2018
|
1,656 | |||
Total
|
3,877 |
-
|
124,000 shares which may be purchased at a price of €2.60 per share pursuant to the exercise of options that were granted in 2004, and
|
-
|
174,100 shares which may be purchased at a price of €2.38 per share pursuant to the exercise of options that were granted on June 25, 2010.
|
June 30, 2013
|
December 31, 2012
|
December 31, 2011
|
||||||||||||||||||||||
Options
|
Weighted
average
exercise
price
(€)
|
Options
|
Weighted
average
exercise
price
(€)
|
Options
|
Weighted
average
exercise
price
(€)
|
|||||||||||||||||||
Outstanding on January 1,
|
810,850 | 3.18 | 830,025 | 3.23 | 906,775 | 3.19 | ||||||||||||||||||
Granted
|
500,000 | 1.91 | - | - | - | - | ||||||||||||||||||
Exercised
|
- | - | - | - | - | - | ||||||||||||||||||
Forfeited
|
(15,750 | ) | 3.17 | (51,750 | ) | 3.03 | ||||||||||||||||||
Expired
|
(3,425 | ) | 2.02 | (25,000 | ) | 2.08 | ||||||||||||||||||
Outstanding at the end of the period
|
1,310,850 | 1.97 | 810,850 | 3.18 | 830,025 | 3.23 | ||||||||||||||||||
Exercisable at the end of the period
|
743,347 | 3. 27 | 675,844 | 3.38 | 621,516 | 3.50 | ||||||||||||||||||
Shares purchase options available for grant on at end of period
|
83,428 | 83,428 | 72,003 |
Outstanding options
|
Exercisable options
|
|||||||||||||||||||
Exercise price (€)
|
Options
|
Weighted
average
remaining
contractual
life
|
Weighted
average
exercise
price
(€)
|
Options
|
Weighted
average
exercise
price
(€)
|
|||||||||||||||
3.99
|
416,838 | 4.3 | 3.99 | 416,838 | 3.99 | |||||||||||||||
2.60
|
124,000 | 0.7 | 2.60 | 124,000 | 2.60 | |||||||||||||||
2.38
|
174,100 | 6.0 | 2.38 | 130,575 | 2.38 | |||||||||||||||
1.91
|
500,000 | 9,5 | 1.91 | - | - | |||||||||||||||
1.88
|
95,912 | 6.0 | 1.88 | 71,934 | 1.88 | |||||||||||||||
1.88 to 3.99
|
1,310,850 | 6.6 | 1.97 | 743,347 | 3.27 |
-
|
Share price at closing date: $2.59
|
-
|
Strike price of warrants: €0.13
|
-
|
Risk free interest rate at 10 years: 2.08%
|
-
|
Share price volatility: 120%
|
6 months
2013
|
6 months
2012
|
|||||||
Interest income
|
37 | 77 | ||||||
Interest expense
|
(1,923 | ) | (1,325 | ) | ||||
Depreciation of prepaid expenses on debt grant
|
- | (31 | ) | |||||
Changes in fair value of the 2007 Convertible Debentures
|
- | (2,345 | ) | |||||
Changes in fair value of the warrants
|
1,274 | (316 | ) | |||||
Total
|
(612 | ) | (3,941 | ) |
6 months
2013
|
6 months
2012
|
|||||||
Segment operating loss
|
(2,649 | ) | (1,943 | ) | ||||
Interest income, net
|
(612 | ) | (3,941 | ) | ||||
Foreign Currency exchange (losses) gains, net
|
(757 | ) | (11 | ) | ||||
Other income, net net
|
1 | 40 | ||||||
Income tax (expense) credit net
|
(61 | ) | (25 | ) | ||||
Consolidated net loss net
|
(4,078 | ) | (5,880 | ) |
HIFU
Division
|
UDS
Division
|
EDAP TMS
Corporate
|
FDA
PMA
|
Total
consolidated
|
||||||||||||||||
6 months 2013
|
||||||||||||||||||||
Sales of Goods
(incl. consumables)
|
650 | 5,294 | — | — | 5,944 | |||||||||||||||
Sales of RPPs & Leases,
|
1,203 | 766 | — | — | 1,970 | |||||||||||||||
Sales of Spare Parts & Services
|
495 | 2,017 | 2,512 | |||||||||||||||||
Total Net Sales
|
2,349 | 8,077 | — | — | 10,426 | |||||||||||||||
Other Revenues
|
3 | - | 3 | |||||||||||||||||
Total Revenues
|
2,352 | 8,077 | 10, 429 | |||||||||||||||||
Gross Profit
|
1,203 | 2,623 | — | — | 3,825 | |||||||||||||||
Research & Development
|
(572 | ) | (363 | ) | — | (645 | ) | (1,578 | ) | |||||||||||
SG&A + Depreciation
|
(1,145 | ) | (2,914 | ) | (761 | ) | (74 | ) | (4,896 | ) | ||||||||||
Operating income (loss)
|
(514 | ) | (654 | ) | (761 | ) | (719 | ) | (2,649 | ) |
HIFU
Division
|
UDS
Division
|
EDAP TMS
Corporate
|
FDA
PMA
|
Total
consolidated
|
||||||||||||||||
6 months 2012
|
||||||||||||||||||||
Sales of Goods
(incl. consumables)
|
466 | 5,746 | — | — | 6,212 | |||||||||||||||
Sales of RPPs & Leases,
|
1,505 | 696 | — | — | 2,201 | |||||||||||||||
Sales of Spare Parts & Services
|
454 | 2,096 | 2,550 | |||||||||||||||||
Total Net Sales
|
2,426 | 8,538 | — | — | 10,963 | |||||||||||||||
Other Revenues
|
(3 | ) | 3 | - | ||||||||||||||||
Total Revenues
|
2,422 | 8,541 | 10,963 | |||||||||||||||||
Gross Profit
|
1,103 | 3,193 | — | -- | 4,296 | |||||||||||||||
Research & Development
|
(717 | ) | (451 | ) | — | (395 | ) | (1,563 | ) | |||||||||||
SG&A + Depreciation
|
(1,349 | ) | (2,697 | ) | (589 | ) | (42 | ) | (4,676 | ) | ||||||||||
Operating income (loss)
|
(964 | ) | 46 | (589 | ) | (437 | ) | (1,943 | ) |
1 Year EDAP TMS Chart |
1 Month EDAP TMS Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions